SCHEMBL171352

SCHEMBL171352

CNC(=O)c1cc(Oc2ccc(CNC(=O)Nc3cc(C)c(Cl)cc3OCCN3CCCC3)cc2C)ccn1

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 3/20 0.65
RAF1 P04049 4/20 0.46
MAPK14 Q16539 2/20 0.45
HTR2A P28223 3/20 0.44
GSK3B P49841 1/20 0.44
KDR P35968 5/20 0.42
FLT1 P17948 4/20 0.42
FLT4 P35916 4/20 0.42
MCHR1 Q99705 1/20 0.41
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40
FGFR1 P11362 1/20 0.39
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171223 0.94 DDR2 (0.63) DDR2RAF1MAPK14HTR2AGSK3B
SCHEMBL13603578 0.94 DDR2 (0.63) DDR2RAF1MAPK14HTR2AGSK3B
SCHEMBL171401 0.93 DDR2 (0.55) DDR2RAF1MAPK14HTR2AGSK3B
SCHEMBL15574596 0.93 DDR2 (0.60) DDR2RAF1HTR2AKDRFLT1
SCHEMBL171252 0.91 DDR2 (0.54) DDR2RAF1MAPK14HTR2AGSK3B
SCHEMBL15575261 0.90 DDR2 (0.55) DDR2RAF1MAPK14HTR2AGSK3B
SCHEMBL16990594 0.89 DDR2 (0.60) DDR2RAF1HTR2AKDRFLT1
SCHEMBL171330 0.88 DDR2 (0.71) DDR2RAF1MAPK14HTR2AGSK3B
SCHEMBL169159 0.88 DDR2 (0.71) DDR2RAF1MAPK14HTR2AGSK3B
SCHEMBL171224 0.88 DDR2 (0.49) DDR2RAF1MAPK14HTR2AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed
US-20130158076-A1 Methylene Urea Derivatives MERCK PATENT GMBH (DE) 2013-06-20 US disclosed
US-8410143-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2013-04-02 US disclosed
US-8410143-B2 Methylene urea derivatives MERCK PATENT GMBH (DE) 2013-04-02 US disclosed
EP-2426122-A1 Methylene urea derivative as RAF kinasse inhibitors Merck Patent GmbH (DE) 2012-03-07 EP disclosed
US-20090298885-A1 METHYLENE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2009-12-03 US disclosed
US-20090298885-A1 METHYLENE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298885-A1 METHYLENE UREA DERIVATIVES BRAF, RAF1, CMPK1 DDR2 4558/4885RAF1 2/4885MAPK14 120/4885
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885RAF1 3072/4885MAPK14 455/4885
US-20130158076-A1 Methylene Urea Derivatives BRAF, RAF1, CMPK1 DDR2 4558/4885RAF1 2/4885MAPK14 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.